Janak Padia

Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease

Wei Zheng, Janak Padia, Daniel J. Urban et al. · Proceedings of the National Academy of Sciences · 2007 · 139 citations · Full text

Pharmacy, Biochemistry, Medicinal Chemistry +17

Novel Nonpeptide CCK-B Antagonists:  Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antagonists

Janak Padia, Mark J. Field, Joanna P. Hinton et al. · Journal of Medicinal Chemistry · 1998 · 85 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Efficient, large-scale synthesis and preclinical studies of MRS5698, a highly selective A3 adenosine receptor agonist that protects against chronic neuropathic pain

Dilip K. Tosh, Janak Padia, Daniela Salvemini et al. · Purinergic Signalling · 2015 · 52 citations

Medicine, Medicinal Chemistry, Pharmacology +15

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model

Hisayuki Yao, Eishi Ashihara, Jeffrey Strovel et al. · Blood Cancer Journal · 2011 · 49 citations · Full text

Life Sciences, Molecular Biology, Oncology +15

Second Generation “Peptoid” CCK-B Receptor Antagonists:  Identification and Development of<i>N</i>-(Adamantyloxycarbonyl)-α-methyl-(<i>R</i>)-tryptophan Derivative (CI-1015) with an Improved Pharmacokinetic Profile

Bharat K. Trivedi, Janak Padia, Ann Holmes et al. · Journal of Medicinal Chemistry · 1998 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12